The Butantan Institute requested the National Health Surveillance Agency (Anvisa) to register the world’s first single-dose dengue vaccine. The information was confirmed by Gustavo Mendes, director of the institute, in an interview with Now CNN .
According to Mendes, the development of the vaccine took around a decade. “Butantan started this development 10 years ago. These studies need very close monitoring and very cautious development”, he explained.
The vaccine, according to the director, showed promising results for all four dengue serotypes. “We know that dengue is a disease that has four serotypes, dengue 1, dengue 2, dengue 3, dengue 4, and we achieved a result that showed promise for all these variants”, he stated.
Single dose and prolonged effectiveness
One of the main differences of the vaccine developed by Butantan is the need for only one dose for immunization. “It is a vaccine that you will only take once and you will not need to take it again, because dengue is not a disease that has this mutation and this characteristic like others, like Covid or the flu”, highlighted Mendes.
The studies carried out by the institute followed the participants for a period of five years, demonstrating that protection is maintained during this time. “During this period we saw that people remained protected”, highlighted the director.
The delivery of the final documentation to Anvisa marks a crucial stage in the vaccine approval process. Mendes emphasized the importance of the partnership between researchers and volunteers, “It was a great partnership that we had in this sense of development. We here in Brazil involved a series of researchers who monitored the people who took the vaccine, monitored whether they had the disease or whether they had a severe case.”
If approved, the Butantan vaccine could represent a significant advance in the fight against dengue, a disease that affects millions of people annually, especially in tropical countries like Brazil.
This content was originally published in Butantan has promising results in a vaccine against all Dengue serotypes on the CNN Brasil website.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
